アブストラクト
| Title | 薬剤性の電解質異常 |
|---|---|
| Subtitle | 特集 最適な治療・管理がわかる 水・電解質・酸塩基平衡異常 注意しておきたい薬剤による電解質異常 |
| Authors | 永山泉, 前嶋明人 |
| Authors (kana) | |
| Organization | 埼玉医科大学総合医療センター腎・高血圧内科 |
| Journal | 月刊薬事 |
| Volume | 66 |
| Number | 5 |
| Page | 836-840 |
| Year/Month | 2024 / 4 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Points」●Na利尿を示す薬剤(ループ利尿薬, サイアザイド系利尿薬)は, 低ナトリウム血症や低カリウム血症を引き起こす. ●ミネラルコルチコイド受容体拮抗薬は高カリウム血症を生じる. ●分子標的薬による電解質異常として, 抗EGFR抗体薬による低マグネシウム血症と抗FGFR抗体薬による高リン血症の頻度が高い. ●糖尿病治療薬による電解質異常には, メトホルミンによる乳酸アシドーシスのほか, SGLT2阻害薬による血清マグネシウム濃度, 血清カリウム濃度, 血清リン濃度の上昇が知られている. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Ramos-Casals M, et al : Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers, 6 : 38, 2020
- 2) Yeung SJ, et al : Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open, 1 : 1637-1659, 2020
- 3) Subbiah V, et al : Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med, 4 : 101204, 2023
- 4) Palmer BF, et al : Kidney-Protective Effects of SGLT2 Inhibitors. Clin J Am Soc Nephrol, 18 : 279-289, 2023
- 5) Tang H, et al : Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia, 59 : 2546-2551, 2016
残りの9件を表示する
- 6) Palmer BF, et al : SGLT2 Inhibition and Kidney Potassium Homeostasis. Clin J Am Soc Nephrol, 2023
- 7) Neuen BL, et al : Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 145 : 1460-1470, 2022
- 8) Fu EL, et al : A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int, S0085-2538 : 00865-00867, 2023
- 9) Refardt J, et al : Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol, 34 : 322-332, 2023
- 10) Sarafidis P, et al : SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication? Am J Nephrol, 51 : 553-555, 2020
- 11) Monnerat S, et al : Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor. J Endocr Soc, 7 : bvad011, 2023
- 12) de Jong MA, et al : Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clin J Am Soc Nephrol, 14 : 66-73, 2019
- 13) Wang X, et al : Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int, 34 : 2013-2025, 2023
- 14) Qian BB, et al : Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int, 31 : 2313-2320, 2020
